Supernus Pharmaceuticals, Inc. (SUPN)
47.16
+0.65
(+1.40%)
USD |
NASDAQ |
Dec 12, 16:00
47.18
+0.02
(+0.04%)
After-Hours: 20:00
Supernus Pharmaceuticals Research and Development Expense (Quarterly): 28.87M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biogen, Inc. | 369.60M |
| BridgeBio Pharma, Inc. | 112.87M |
| CorMedix, Inc. | 5.098M |
| Assembly Biosciences, Inc. | 16.56M |
| Viking Therapeutics, Inc. | 89.95M |